drugset
drugset / Trial / NCT02768766

Intermittent Selumetinib for Uveal Melanoma

NCT02768766 ↗

Phase 1 Completed 42 enrolled Shaheer A. Khan AstraZeneca · collabMelanoma Research Alliance · collab
Non-randomizedSequentialOpen-labelTreatment

Summary

The purpose of this study is to find out what effects, good and/or bad, intermittent dosing of the drug Selumetinib will have on subjects with uveal melanoma. Selumetinib is a drug that blocks (or turns off) methyl ethyl ketone (MEK), a protein activated in some uveal melanoma cells. Selumetinib is a MEK inhibitor. Blocking MEK may stop the cancer from growing.

Timeline

Start
2017-02-28
Primary completion
2020-09-18
Completion
2020-09-18

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Selumetinib Small molecule 100 mg Oral
Subject Selumetinib Small molecule 125 mg Oral
Subject Selumetinib Small molecule 150 mg Oral
Subject Selumetinib Small molecule 175 mg Oral
Subject Selumetinib Small molecule 200 mg Oral
Subject Selumetinib Small molecule 225 mg Oral

Indications

uveal melanoma